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tion occurred among 36% and 50% of P-PGI2 and NP-PGI2 patients, respectively; mean 
(SD) weeks to augmentation were 7 (15) and 3 (8). ConClusions: Use of other PAH 
therapies prior to PGI2 is common, particularly among NP-PGI2. Our findings suggest 
that parenteral PGI2 may be reserved for more severe PAH patients.
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objeCtives: The long-term use of ß-blockers has been shown to improve the out-
comes of patients with heart failure (HF). However, it is still disputed whether this 
is a class effect, and, specifically, whether carvedilol or bisoprolol are superior to 
metoprolol tartrate. The objective of this study is to compare the effectiveness of 
ß-blockers for patients with HF in a clinical practice. Methods: We conducted an 
observational cohort study using the Quebec administrative databases to identify 
patients with HF who were prescribed a ß-blocker after the diagnosis of HF e.g. 
metoprolol tartrate, carvedilol or bisoprolol. We used descriptive statistics to charac-
terize the patients by the type of ß-blocker prescribed at discharge. The unadjusted 
mortality for users of each ß-blocker was calculated using Kaplan-Meier curves and 
compared using the log-rank test. To account for differences in follow-up and to 
control for differences among patient characteristics, a multivariate Cox propor-
tional hazards model was used to compare the all-cause mortality, cardiovascular 
mortality and HF readmission. We run also analysis by matching with a propensity 
score. Results: Of the 3,732 patients with HF, with a median follow-up of 3.1 years 
per patient, the crude annual incidence of death was 16.5% with metoprolol tartrate, 
15.8% with carvedilol, and 17.5% with bisoprolol. After controlling for several dif-
ferent covariates, we found that carvedilol (hazard ratio [HR] 0.95, 95% confidence 
interval [CI] 0.82-1.10) and bisoprolol (HR 1.06, 95% CI 0.95-1.18) were not superior to 
metoprolol tartrate in improving survival. Similar results were observed for cardio-
vascular mortality. But, HF readmission rate was significantly increased from 20 to 
26% with carvedilol and bisoprolol compare to metoprolol tartrate. ConClusions: 
Based on observational study, we suggest that there is no evidence of a class effect 
for β -blockers in older patients with HF on mortality, but the choice of β-blocker may 
have impact on the rate of HF readmission.
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objeCtives: Dyslipidaemia is an important and well recognised modifiable CV 
risk factor. This study was undertaken to determine the proportion of patients 
reaching and maintaining the low-density lipoprotein cholesterol (LDL-C) target in 
a large Canadian cohort and the prevalence of CV risk factors. Methods: We ret-
rospectively analysed data from an open cohort of patients initiating statin therapy 
between 2004 and 2012, using the Southwestern Ontario primary care practice data-
base. Inclusion criteria were: ≥ 2 years statin-free, diagnosis of dyslipidaemia, and ≥ 1 
statin prescription. Patients were stratified into three CV risk levels (low, intermedi-
ate, high); results are reported for the high-risk subgroup. CV risk factors and preva-
lence were estimated using 2012 data. Results: Of 41,733 patients who initiated 
statin therapy, 14,607 (35%) were at high CV risk. At baseline, the mean±SD age was 
54±7 years, 51% were male, and LDL-C was 3.07±0.41 mmol/L. In 2012, there were 
13,985 high-risk patients, with a mean±SD of 3±2 CV risk factors. The most frequent 
CV risk factors were: age (females > 55 years + males > 45 years: 91%, n= 12,727), 
obesity (body mass index > 27 kg/m2: 36%, n= 5,035), high-risk hypertension (31%, 
n= 4,395), history of CV disease (17%, n= 2,377), and diabetes (14%, n= 1,958). Among 
high-risk patients in 2012, 1,390 (10%) received no statins, of whom 1,266 (91%) had 
statin intolerance (SI) and only 17 (< 1%) received no lipid-lowering agent. Across 
2004–2012, patients took 6.7±2.2 months to reach the LDL-C target. After 1 year of 
statin treatment, 25% (n= 3,652) had not reached the target; this proportion remained 
stable over time. Among the 1,294 patients with SI, 84% were on target at SI diag-
nosis and only 49% were still on target 6 months post-SI. ConClusions: Despite 
widespread statin use, dyslipidaemia represents a significant burden for high-risk 
patients. Many patients do not achieve their LDL-C goals with statin therapy.
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objeCtives: Estimate annual utilization and cost of prostacyclins (PGI2) among 
patients with pulmonary arterial hypertension (PAH). Methods: Truven® 
Commercial and Medicare Databases were used to identify annual cohorts of adults 
with PAH (i.e., International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) diagnosis codes [416.0 or 416.8] and ≥ 1 claims for PAH-
specific medications) between calendar-year (CY) 2010 and CY2014. Patients with 
≥ 1 claims for PGI2 were deemed PGI2 users. PGI2 use was categorized as parenteral 
vs. non-parenteral. PAH-related included costs of PAH-specific medications and all 
medical claims with a relevant diagnosis code. Results: A total of 12,306 patients 
met selection criteria for at least 1 CY of the study period. Annual prevalence of 
PGI2 use ranged from 20% to 22%. Among PGI2 users, treprostinil use increased 
from 50% in CY2010 to 71% in CY2014; corresponding decreases for epoprostenol 
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objeCtives: To assess, in a community setting, the clinical and economic outcomes 
of hypercholesterolemic patients with ACS and diabetes treated with statins over 
a one-year follow-up. Methods: Data for over 2.9 million subjects were extracted 
from 6 Local Health Units (ARNO Observatory, an administrative database contain-
ing data on hospitalizations, prescriptions and diagnostic/outpatient visits). The 
index period lasted from January 1 to December 31, 2011. Patients with ACS and dia-
betes were followed-up from the index hospitalization in 2011 for a period of 1 year. 
The rate of prescription, dosage, adherence to statin treatment and related health 
care costs were evaluated. Results: Of 2,989,512 subjects identified, 6,226 patients 
(0.2%) were hospitalized for ACS: 86.4% were aged over 60 years. Hospital death rate 
was 4.1%. Among ACS cases, 1,917 had diabetes (30.8%). At 1-year follow-up, 85.3% 
of patients with ACS and diabetes, were prescribed statin therapy with 84.9% being 
prescribed high intensity statins (Atorvastatin 40, 80 mg/dL, Rosuvastatin 20, 40 mg/
dL). Adherence to treatment (attributed to all patients who received the correct daily 
dosage during the one year follow-up period with a 20% tolerability – CORE Study 
2013) was higher among high intensity statins users compared to lower intensity 
statins users (67.1% vs 38.9%). Over the 1-year follow-up period, 69.3% of ACS dia-
betic patients were re-hospitalized, of which 55.6% were hospitalized for cardiovas-
cular events. The average yearly cost per patient supported by NHS was 16,897€ /year: 
14,199€ for hospitalizations; 1,691€ for drugs; 1,008€ for diagnostic and outpatient 
visits. ConClusions: Patients with ACS and diabetes have high direct healthcare 
costs, with re-hospitalization being the main cost driver. Adherence to statin treat-
ment was sub optimal. Local Health Authorities together with Cardiologists and 
GPs are working to bridge the gap between evidence-based recommendations and 
clinical practice in order to contain morbidity and health costs.
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objeCtives: Previously, we reported lipid modifying therapy (LMT) and low-density 
lipoprotein cholesterol (LDL-C) goal attainment among patients at high-risk for 
cardiovascular events. The objective of the current study was to describe clinical 
characteristics, lipid modifying therapy (LMT) treatment, and LDL-C attainment of 
a familial hypercholesterolemia (FH) cohort. Methods: For this cross-sectional 
study, the PHARMO Database Network was used. Patients aged ≥ 18 years with an 
LDL-C measurement in 2012 (index date) and ≥ 2 years of continuous enrollment 
in the pre-index period were considered. We identified FH patients by searching 
for a diagnosis of FH recorded by a general practitioner (GP) in the 2-year pre-index 
period or by application of the Dutch Lipid Clinic Network (DLCN) criteria (score 
≥ 6). Patients with a filled prescription for LMT within 45 days of index were con-
sidered to be taking the medication. LDL-C goal of ≤ 100mg/dL was considered at 
goal. Results: 1,132 patients were identified, with 92% having a recorded FH diag-
nosis by a GP. Mean (±SD) age was 57 (±14) years and 43% were male. Approximately 
33% had co-morbid diabetes, 42% had hypertension and the mean (±SD) LDL-C was 
138 (±58) mg/dL In total, 54% were currently treated with LMT; 13% high-intensity 
statin (atorvastatin 40/80mg, rosuvastatin 20/40mg, simvastatin 80mg); 39% mod-
erate-to low-intensity statin and 2% other non-statin LMT. LDL-C ≥ 100 mg/dl was 
observed in 77% of the patients and 27% had an LDL-C ≥ 160mg/dL. Among the 47% 
not currently treated with LMT, 89% had an LDL-C level ≥ 100 mg/dl and 74% had no 
evidence of any LMT in the pre-index period. ConClusions: These data suggest 
that FH patients in the Netherlands are undertreated by GPs and not at goal. This 
underscores the need for improving treatment rates with LMT and benefit of add-on 
treatment options in those not able to achieve goals on current LMTs.
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objeCtives: Describe demographics, clinical characteristics and treatment patterns 
(i.e., discontinuation, switching, or augmentation) of patients with pulmonary arterial 
hypertension (PAH) initiating prostacyclin (PGI2) therapy. Methods: Using Truven® 
Commercial and Medicare Databases (2010–2014), two non-mutually exclusive cohorts 
were constituted. The first consisted of initiators of parenteral PGI2 (P-PGI2); the sec-
ond, non-parenteral PGI2 (NP-PGI2). All patients were required to have evidence of 
PAH (i.e., ≥ 1 claims with a PAH diagnosis or ≥ 1 pharmacy claims for PAH-specific 
medications). Demographics and clinical characteristics were assessed during the 
three months prior to PGI2 initiation. Treatment patterns were assessed until switch/
discontinuation, or end of follow-up. Results: Of the 12,306 PAH patients identified 
during the study period, 1,569 (12.7%) were new initiators of PGI2 (755 [6.1%] for P-PGI2 
and 1,003 [8.2%] for NP-PGI2). Approximately 70% of each cohort was female. P-PGI2 
patients were nominally younger than NP-PGI2 patients (54.2 vs. 59.4 years), yet, had 
more comorbidities, hospitalizations, emergency room visits and mean (standard 
deviation [SD]) PAH-related medical costs than NP-PGI2 patients ($46,038 [$72,208] 
vs. $28,210 [$58,386]) during the three months before PGI2 initiation. P-PGI2 patients 
had less other PAH medication use than NP-PGI2 patients prior to PGI2 initiation (43% 
vs. 67%). Twenty-seven percent and 19% of P-PGI2 and NP-PGI2 patients, respectively, 
discontinued initial PGI2; mean (SD) weeks to discontinuation was 22 (35) and 20 (23). 
Only 7% of P-PGI2 and 11% of NP-PGI2 patients switched; mean (SD) weeks to switch 
was approximately 8 (12.5) in both groups. Augmentation with another PAH medica-
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classified according to the first drug dispensing during 6 months from the discharge 
date. Patients were categorized in low ischemic stroke (CHA2DS2-VASc) (LR, score= 0), 
moderate-risk (MR, score= 1), high-risk (HR, score≥ 2).Multivariable logistic regression 
was used to evaluate the associations between ischemic stroke and bleeding (HAS-
BLED) risk with the choice of non-vitamin K antagonist oral anticoagulants (NOACs) 
versus vitamin K antagonists (VKAs) therapy. Results: A total of 1,963 patients were 
identified: 4.9% LR, 7.6% MR and 87.5% HR patients. Overall, 36.4% of patients were 
not treated (LR: 56.7%, MR: 55.0%, HR: 33.7%patients). Among patients treated, VKA in 
monotherapy was prescribed to 26.7% of the patients (LR: 23.8%, MR: 26.9%, HR: 26.8%), 
aspirin in monotherapy to 27.5% (LR: 31.0%, MR: 34.3%, HR: 27.0%), NOAC in mono-
therapy to 19.3% (LR: 23.8%, MR: 17.9%, HR: 19.2%), other antiplatelet in monotherapy 
to 19.4% (LR: 16.7%, MR: 13,4%, HR: 19.8%), and associations to 7.1% (LR: 4.8%, MR: 
7.5%, HR: 7.2%). The ischemic stroke and bleeding risks were not significantly associ-
ated with the choice of anticoagulant drug. ConClusions: High proportion of NVAF 
patients with moderate or high stroke risk did not receive antithrombotic therapy 
as recommended by guidelines. Moreover, aspirin was commonly prescribed even in 
HR patients. The risk stratification did not influence the choice of anticoagulant drug.
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objeCtives: The aim of this study was to assess the prevalence and characteristics 
of subjects with a recent ACS episode (in the year preceding statin prescription) 
appropriately treated with high-efficacy statins, and who have inadequate control of 
LDL-C levels, despite being adherent to treatment Methods: An observational ret-
rospective cohort analysis based on five Local Health Units administrative databases 
was conducted, for a total number of 1.2 Million beneficiaries. Patients who have 
been hospitalized with ICD9 code 410 in the year preceding their first statin pre-
scription (between January 1, 2011 and December 31, 2012) were included. Patients 
were characterized back 12 months from index date to assess appropriateness and 
adherence to statin treatment Results: Among patients with recent ACS enrolled 
(1’098 patients), 549 (50%) had no LDL-C determination, 335 (31%) and 214 (19%) 
displayed LDL-C under control and out of control, respectively. Among patients 
with uncontrolled LDL-C, 16 (7%) and 198 (93%) were not treated and treated with 
statins, respectively. Among patients with statins treatment, 27 (14%) and 171 (86%) 
were treated with low and high efficacy statins, respectively. Finally, among patients 
treated with high efficacy statins, 115 (67%) and 56 (33%) were non-adherent and 
adherent to high efficacy statin treatment, respectively. LDL-C uncontrolled high 
efficacy adherent patients showed different distances from their lipid target: 33.9% 
were less than 10% distant, 16.1% were 10-19% distant, 14.3% were 20-29% distant, 
12.5% were 30-39% distant and 23.2% were more than 40% distant ConClusions: 
These results are topical, as new monoclonal antibodies are being marketed to 
address the unmet need in cholesterol statin-management of dyslipidaemia for 
uncontrolled patients. By projecting study percentages to the Italian population, 
the number of LDL-C measured patients with a recent ACS episode who are uncon-
trolled, despite being adherent to a high efficacy statin, would be around 6’524
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objeCtives: In Japan, real-world evidence regarding impact of obesity on the preva-
lence of hypertension is lacking. The objective of this study was to investigate the 
prevalence and treatment status of hypertension in obese patients, with a focus on 
resistant hypertension. Methods: This was a retrospective study using a Japanese 
healthcare database composed of annual health checkup and claims data (MinaCare 
Co. Ltd.). Subjects aged > = 20 years at 2012 health checkup with 2 years (2011/2012) of 
checkups were selected for the study. Diagnosed hypertensive subjects (ICD-10 codes 
I10-I15) who were prescribed with antihypertensive medications within 1 year prior to 
checkup were defined as “treated”. Resistant hypertension was defined as uncontrolled 
hypertension (SBP/DBP> = 140/90mmHg) with 3 classes of antihypertensives including 
diuretics, or the use of > = 4 classes. Results: A total of 462,323 subjects (32% female, 
68% male) were analyzed. The age category 40-< 50 years accounted for the largest 
proportion (35%) of the sample. The mean BMI was 21.8/23.7 and the proportion of 
obese subjects (BMI> = 25) was 16.0%/29.9% (female/male). Approximately 10.4% of the 
subjects were “treated”. For each age, sex, and treatment category, the prevalence of 
hypertension (defined as SBP/DBP> = 140/90mmHg or “treated”) increased with increas-
ing BMI. In particular, males in 40-< 50 age category, odds-ratio for the prevalence of 
hypertension versus BMI 18.5-< 25 were 0.601, 3.607, 7.405, 15.445 for BMI categories 
< 18.5, 25-< 30, 30-< 35, 35-< 40, 40-, respectively. The prevalence of resistant hyperten-
sion among those diagnosed and prescribed with antihypertensives was consistently 
higher for obese subjects (vs non-obese) for each sex and age category; in particular, it 
was 4.1% (obese) vs 8.7% (non-obese) for males in 40-< 50 age category. ConClusions: 
We demonstrated that prevalence of resistant hypertension as well as that of hyper-
tension increased with increasing BMI using healthcare database in Japan. These 
results reconfirm the impact of obesity in the treatment and control of hypertension.
PCV41
ePidemiology of stAtin-treAted PAtients with unControlled ldl 
leVels from itAliAn AdministrAtiVe offiCiAl dAtABAses
Degli Esposti L, Sangiorgi D, Crovato E, Buda S
CliCon S.r.l., Ravenna, Italy
objeCtives: The aim of this study was to assess the prevalence and character-
istics of subjects appropriately treated with high-efficacy statins, and who have 
and iloprost were 31% to 22% and 26% to 10%, respectively. Use of other PAH-specific 
medication among PGI2 users increased over time, from 62% in CY2010 to 69% in 
CY2014. Mean (standard deviation [SD]) annualized PGI2 costs ranged from $99,919 
($100,139) to $118,861 ($136,493) per CY. Use of parenteral PGI2 decreased over time 
(from 63.2% in CY2010 to 52.4% in CY2014), whereas non-parenteral PGI2 usage 
increased (from 39.7% to 49.5%). Other PAH-specific medications were used in the 
same CY for 74.1%–77.6% of non-parenteral PGI2 users, compared to 54.4%–64.3% 
of parenteral PGI2 users. Mean parenteral PGI2 costs in CY2010 were twice those 
of non-parenteral PGI2. By CY2014, parenteral PGI2 costs were 8% lower than non-
parenteral costs. Mean (SD) PAH-related costs ranged from $189,763 ($167,329) dur-
ing CY2010 to $199,336 ($194,638) during CY2013. ConClusions: While overall use 
of PGI2 was constant over the five-year period, our findings suggest a shift towards 
non-parenteral PGI2 and PGI2 combination therapy in clinical practice.
PCV36
the AnAlyze of ConsumPtion of fixed ComBinAtions of drugs in 
therAPy of hyPertension
Milijasevic B, Savic L, Tomic Z, Sabo A, Milijasevic D, Tomic N
Medical Faculty of Novi Sad, University of Novi Sad, Novi Sad, Serbia and Montenegro
objeCtives: Hypertension is one of the major risk factors for occurrence cardiovas-
cular disease. Drugs of the first choice in the treatment of hypertension are: diuretics, 
beta adrenergic blockers, calcium channel blockers, angiotensin converting enzyme 
inhibitors and inhibitors of angiotensin II receptor. Fixed combinations of antihyper-
tensive drugs simplify treatment and enhance patient compliance. The aim of this 
study was to analyze consumption fixed combinations of drugs for the treatment of 
hypertension in the Republic of Serbia in the 2011-2012 year and to compared it with 
the results of Finland and Norway in the same period. Methods: Consumption of 
officinals is expressed by the number of defined daily doses per 1000 inhabitants per 
day (DDD) according to the anatomical therapeutic chemical classification. Data on 
consumption of drugs are taken from the official web site for the period 2007– 2012. 
year from the Agency for drugs and medical devices of Serbia, Finnish Medicines 
Agency Fima and Norwegian Institute of Public Health. Results:: Fixed combina-
tion of converting enzyme inhibitors with diuretics are most frequently used drugs 
in Serbia (2007 (18,86 DDD), 2008 (26,61 DDD), 2009 (30,77 DDD), 2010 (27,30 DDD), 2011 
(43,72 DDD) and 2012 (55,52 DDD)) compared with Norway and Finland. The use of 
these drugs is on the rise in Serbia. In the opposite side use of angiotensin II antago-
nists and diuretics in Serbia is significantly lower (2007 (0,10 DDD), 2008 (0,07 DDD), 
2009 (0,12 DDD), 2010 (0,19 DDD), 2011 (0,73 DDD) and 2012 (1,70 DDD)) compared with 
Norway and Finland. ConClusions: Based on the results, we concluded that the use 
of fixed combination of drugs in therapy of hypertension in Serbia must be modified. 
This research was supported by Provincial Secretariat for Science and Technological 
Development, Autonomous Province of Vojvodina project No 114-451-2458/2011 and 
by Ministry of Science, Republic of Serbia, project no 41012
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objeCtives: To assess, in a community setting, the clinical and economic outcomes 
of individuals with diabetes at very high cardiovascular (CV) risk (patients with type 
2 or type 1 diabetes, with target organ damage, such as microalbuminuria - ESC/
EAS Guidelines 2011). Methods: Data for over 2.9 million subjects were extracted 
from 6 Local Health Units (ARNO Observatory, an administrative database containing 
data on hospitalizations, prescriptions and diagnostic/outpatient visits). The index 
period lasted from January 1 to December 31, 2011. Results: Of the 2,989,512 sub-
jects identified, 101,217 patients (3.4%) had diabetes with very high CV risk. 82.9% 
were aged over 60 years. At 1-year follow-up, 46.1% were prescribed statin therapy, 
of which 56.9% being prescribed high intensity statins (Atorvastatin 40, 80 mg/dL, 
Rosuvastatin 20, 40 mg/dL). Adherence to treatment (20% tolerability in one year 
follow-up treatment - CORE Study 2013) was higher among high intensity statin users 
compared to low intensity statin users (53.6% vs 40.1%). Over the 1-year follow-up 
period, 23,116 patients (22.8%) were hospitalized for any CV events. The average 
yearly cost per patient, on the high risk diabetic patients, supported by NHS was 
3,001 € /year (hospitalizations: 1,555€ ; drugs: 998€ ; diagnostic and outpatient vis-
its: 449€ ). ConClusions: In this community hospital setting, diabetic patients at 
very high risk of CV were frequently hospitalized for CV events. Although at high 
risk, less than 50% of patients was prescribed on statin therapy and adherence was 
suboptimal. Individuals with diabetes at very high CV risk utilize a significant por-
tion of economic resources, hospitalization being the main cost driver. Local Health 
Authorities together with Physicians and Patient Associations are working to close 
the gap between the existing evidence-based recommendations and current clinical 
practice which could result in a reduction of both diabetes morbidity and health cost.
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objeCtives: To assess the level of adherence to the guidelines for the preven-
tion of thromboembolic risk in patients with Non-Valvular Atrial Fibrillation 
(NVAF). Methods: A population-based cohort study was conducted using admin-
istrative data from a local health authority in the Campania Region (~1,000,000 
inhabitants). NVAF was defined as one or more claims for atrial fibrillation (ICD-
9-CM code 427.31) between July, 2013 and June, 2014 where none of the claims were 
associated with cardioversion or cardiac ablation during the identification period 
and there was no evidence of valve-related diagnoses or procedures. The cohort was 
